Chronic Obstructive Pulmonary Disease (COPD)
The FDA has approved updated labeling for Stiolto Respimat to include COPD exacerbation data and a revised indication.
Patients who received a discharge care bundle after being hospitalized for an acute exacerbation of COPD had a lower rate of readmission.
Patients with chronic obstructive pulmonary disease who used opioids were more likely to be intubated during their hospitalization compared with nonopioid users
There was a trend toward a reduction in mortality in patients with COPD who received beta-blocker treatment compared with patients who did not.
Major cardiovascular adverse events were more common in the previous event subgroup, with 5.5% occurring in the aclidinium group and 6.2% in the placebo group.
Patients with severe COPD improved significantly in both endurance time and walking distance with the use of automatically titrated oxygen flow vs constant oxygen flow.
Treatment with prophylactic antibiotics was associated with a reduction in the frequency of COPD exacerbations and improved quality of life.
No meaningful associations were detected in procedural listing preferences and survival outcomes in patients with COPD or interstitial lung disease awaiting lung transplant.
Clinicians are eager for new therapies to address the damage to airways and lung parenchyma because no current therapy can completely reverse COPD damage.
After 12 months, patients in the Urban Training™ group had increased their number of daily steps by 816 compared with 64 steps in the usual care group.
Additional bronchodilation and hyperinflation reduction occurred in COPD when RPL554, an inhaled PDE 3 and 4 inhibitor, was combined with standard bronchodilators.
Changing pollination patterns, extreme weather events, rising sea levels, air pollution, and extreme temperatures all negatively affect respiratory conditions.
There were no statistically significant differences in mortality rates, rates of COPD exacerbations, lung inflammation, or serious adverse events between a once-daily combined inhaled corticosteroid/LABA and LAMA.
A total of 35% of heroin smokers screened positive for COPD.
Pooled data from two identical 12-week pivotal Phase 3 trials (N=1229) in patients with moderate to very severe COPD showed that the mean annualized rate of all COPD exacerbations was 0.47, 0.45, and 0.55 for revefenacin 175mcg/day, 88mcg/day, and placebo, respectively.
No difference in exacerbations with indacaterol/glycopyrronium for non-frequently exacerbating COPD.
First bronchoscopic lung volume reduction using endobronchial valve performed at Temple University in Philadelphia, PA.
In their Complete Response Letter, the FDA stated that they require more clinical data to support approval.
Cardiovascular risk within 30 days of therapy start was approximately 2-fold higher with the incident use of tiotropium in COPD.
In patients with emphysema, deposition fraction was significantly lower than in other individuals, but no significant differences were found between healthy never smokers and current or former smokers.
Thigh muscle volume showed significant improvements in patients with COPD who were treated with bimagrumab vs placebo.
Patients with COPD who have comorbidities are less likely to receive beneficial treatment for exacerbations.
The incidence of undiagnosed COPD was 26%, and based on the GOLD spirometry grading system, 95% had mild to moderate disease.
Although the summer season yielded the lowest overall COPD exacerbation rate, 43% of exacerbations during summer were moderate to very severe.
The average annual prevalence of bronchiectasis from 2012 to 2014 was 701 cases per 100,000 individuals.
S pneumoniae colonization was positively associated with H influenza colonization, whereas negative associations were reported between P aeruginosa and H influenzae and between P aeruginosa and M catarrhalis.
Comorbid chronic rhinitis is significantly associated with 30-day hospital readmissions related to asthma and chronic obstructive pulmonary disease.
Prior use of systemic corticosteroids and prior isolation of Pseudomonas aeruginosa were risk factors associated with the presence of Pseudomonas aeruginosa in COPD.
Through Bluetooth technology, clinicians and patients will be able to share and monitor inhaler usage.
Short-term corticosteroids may be sufficient for treating patients with acute COPD exacerbations.